A randomised phase II study of pemetrexed versus pemetrexed + erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer

European Journal of Cancer

Volumn 50, Issue 9, 2014, Pages 1571-1580

  Dittrich, Christian ^a   Papai Szekely, Zsolt ^b   Vinolas, Nuria ^c   Sederholm, Christer ^d   Hartmann, Joerg T ^e   Behringer, Dirk ^f   Kazeem, Gbenga ^g   Desaiah, Durisala ^g   Leschinger, Monika I ^h   Von Pawel, Joachim ⁱ  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b Saint George Hospital of Fejér County   (Hungary)

^c HOSPITAL CLÍNIC   (Spain)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e Department of Internal Medicine II Hematology and Medical Oncology ^*  (Germany)

^f Clinic of Hematology and Oncology   (Germany)

^g ELI LILLY AND COMPANY   (United States)

^h LILLY DEUTSCHLAND GMBH   (Germany)

ⁱ ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

Author keywords

Erlotinib; Non small cell lung cancer; Non squamous; Pemetrexed; Second line therapy

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; ERLOTINIB; FOLIC ACID; PEMETREXED;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; COMPARATIVE STUDY; CONTROLLED STUDY; CYTODIAGNOSIS; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTATIC NON SQUAMOUS NON SMALL CELL LUNG CANCER; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT RESPONSE;

ERLOTINIB; NON-SMALL CELL LUNG CANCER; NON-SQUAMOUS; PEMETREXED; SECOND-LINE THERAPY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84901244141     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.03.007     Document Type: Article

References (23)

1. T.E. Stinchcombe, and M.A. Socinski Current treatments for advanced stage non-small cell lung cancer Proc Am Thorac Soc 6 2009 233 241
2. E. Massarelli, and R.S. Herbst Use of novel second-line targeted therapies in non-small cell lung cancer Semin Oncol 33 1 Suppl. 1 2006 S9 S16
3. D.R. Gandara, P.C. Mack, and T. Li et al. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking towards 2012 Clin Lung Cancer 10 2009 392 394
4. Taxotere (docetaxel) Highlights of Prescribing Information 2004 Aventis Pharmaceuticals Inc. New Jersey, USA Available at: < http://products.sanofi. us/taxotere/taxotere.html > [accessed 08/26/2013]
5. Alimta (pemetrexed) Highlights of Prescribing Information 2004 Eli Lilly and Company Indianapolis, USA Available at: < http://pi.lilly.com/us/alimta- pi.pdf > [accessed 08/26/2013]
6. Tarceva (erlotinib) Highlights of Prescribing Information 2010 Genentech USA Inc. California, USA Available at: < http://www.osip.com/pdf/Tarceva-PI- 042010.pdf > [accessed 08/26/2013]
7. M. Di Maio, P. Chiodini, and V. Georgoulias et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small cell lung cancer J Clin Oncol 27 2009 1836 1843
8. T. Li, Y.H. Ling, and I.D. Goldman et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 13 2007 3413 3422
9. E. Giovannetti, C. Lemos, and C.H. Tekle et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells Mol Pharmacol 73 2008 1290 1300
10. M. Ranson, M. Reck, and A. Anthoney et al. Erlotinib in combination with pemetrexed for patients with advanced non-small cell lung cancer (NSCLC): a phase I dose-finding study Ann Oncol 21 2010 2233 2239
11. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
12. N. Hanna, F.A. Shepherd, and F.V. Fossella et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
13. Alimta EMEA label: http://www.emea.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000564/human-med-000638.jsp [accessed 08/26/2013].
14. S. Mirsadraee, D. Oswal, and Y. Alizadeh et al. The 7th lung cancer TNM classification and staging system: review of the changes and implications World J Radiol 4 2012 128 134
15. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2009 205 216
16. M.E. Stokes, C.S. Davis, and G.G. Koch Categorical data analysis using the SAS system 1995 Carey NC
17. F.A. Shepherd, J. Dancey, and R. Ramlan et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
18. E.S. Kim, V. Hirsh, and T. Mok et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
19. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
20. G. Zalcman, E. Bergot, and C.H. Creveuil et al. Integrating biomarkers into clinical trials: methodological issues for a new paradigm in non-small cell lung cancer Curr Opin Oncol 23 2011 106 111
21. M.S. Tsao, A. Sakurada, and J.C. Cutz et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
22. D.H. Lee, J.S. Lee, and S.W. Kim et al. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never smoker patients with non-squamous advanced non-small cell lung cancer Eur J Cancer 49 2013 3111 3121
23. G.R. Oxnard, and P.A. Jänne KRAS wild-type lung cancer: a moving target in an era of genotype migration J Clin Oncol 30 27 2012 3322 3324